Melatonin for the Treatment of Insomnia in Children and Adolescents


( Last Updated : June 10, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1423-000

Details


Question

  1. What is the clinical effectiveness of melatonin versus no treatment or placebo for the treatment of insomnia in children and adolescents?
  2. What is the clinical effectiveness of melatonin versus prescription sedatives for the treatment of insomnia in children and adolescents?
  3. What is the cost-effectiveness of melatonin versus no treatment or placebo for the treatment of insomnia in children and adolescents?
  4. What is the cost-effectiveness of melatonin versus prescription sedatives for the treatment of insomnia in children and adolescents?
  5. What are the evidence-based guidelines regarding the use of melatonin for the treatment of insomnia in children and adolescents?

Key Message

There is some evidence of benefit of melatonin compared with placebo for the short-term treatment of insomnia in children and adolescents with neurodisabilities.

The short-term safety profile of melatonin suggested that it was well-tolerated, although some severe adverse events may occur. There was a lack of long-term safety data.

The American Academy of Neurology guideline recommends high-grade melatonin should be prescribed for treatment of sleep disturbance in children and adolescents with autism spectrum disorder if first-line treatment with behavioural strategies is not helpful.

Evidence comparing the clinical effectiveness of melatonin with prescription sedatives for the treatment of insomnia in children and adolescents was not identified.

No evidence was found regarding the cost-effectiveness of melatonin compared with placebo or prescription sedatives for the treatment of insomnia in children and adolescents.